Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
about
Rosiglitazone for type 2 diabetes mellitusTherapy insight: heart disease and the insulin-resistant patient.Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Radionuclide imaging of myocardial metabolismTranslation of myocardial metabolic imaging concepts into the clinics.Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysisThe effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease.Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer.Nonischemic heart failure in diabetes mellitus.Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy.Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Impact of sex on the heart's metabolic and functional responses to diabetic therapies.Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications.Exposure to rosiglitazone, a PPAR-γ agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus.Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy.Recent advances in metabolic imaging.Imaging of myocardial fatty acid oxidation.Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation.In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats.In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes.Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy.Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.Myocardial glucose uptake in patients with the m.3243A > G mutation in mitochondrial DNA.Positron emission tomography for the evaluation and treatment of cardiomyopathy.Diabetic cardiomyopathy
P2860
Q24243875-82C1F7D5-2066-453C-A076-91FF4CB662AFQ30351748-CFB539DD-DBF1-4F68-B662-506F694B6B9AQ30353176-1A00826E-9FE9-4E8D-91C0-A3009E730030Q33943594-CA081BE6-C8B1-411E-AC5E-B667DDFBE597Q34089975-E400EBDC-89F1-4579-A4D8-B9EABB99B03AQ35592932-0164676F-1055-452A-AFF4-F53958555882Q35612747-B721608B-E589-44D4-8B8A-B2A229A7A22AQ36698721-C3A387E3-63C2-4FE7-8675-562D0415C34AQ36762969-53EFE48E-CDA9-4A9B-A544-61384C6E5502Q36844816-84D0717F-EB8D-40B5-9323-C8BEF42B091DQ36857263-B0170CDF-CC92-4DAA-8474-188C6284BCA8Q37107490-C257FDF8-407D-4805-BD2D-6E92685CD725Q37440251-3E8CB8C5-DE2A-4288-80EC-771EC50CDF79Q37457580-75B08CC9-B3EC-4F23-811B-9665C47FAB26Q37602891-FD9FAFA3-9355-46E0-AE97-A7F517C65E34Q37629364-7B29010F-0EA9-4F12-B1EE-F967D53203A3Q38083574-D090719B-2328-4C27-B745-766B5DFC8968Q38156683-84A1C00A-59C1-4153-9408-D9942016FED8Q38753602-B4DD5151-E86F-4F35-AD69-93494AFC6E2DQ40123899-AD4588BA-A8CE-4588-AF45-12B04C0C71A0Q41534968-8DD26B27-C3D4-40BF-B4CB-CFEF73295232Q41832683-79D60E83-2C52-4D2D-8FEA-84A9F20B1568Q42409105-870B5E3D-0476-4D70-BAAD-BC700BB92585Q42487926-D8CC7EA1-65D4-4B12-A87A-253B5D41C425Q42874888-8BBE5B50-90BB-4283-B05D-F7BDE2679B0FQ43172662-341BB858-9484-4864-9C02-13A43851715CQ47785505-E753FA6B-872F-4479-85DC-CEAC6867B1ABQ51300770-F8AF3FC7-7ED2-480D-BC08-F4E8821FD91FQ53236739-1175BE7F-1364-4A18-94C8-FB67D0AC8E07Q57186141-6E39ACB3-64BC-4D08-8E61-7F2E400541A1
P2860
Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@en
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@nl
type
label
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@en
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@nl
prefLabel
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@en
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@nl
P2093
P2860
P1433
P1476
Enhancement of insulin-stimula ...... es treated with rosiglitazone.
@en
P2093
Hällsten K
Janatuinen T
Lehtimäki T
Lönnqvist F
Rönnemaa T
Turiceanu M
Virtanen KA
P2860
P304
P356
10.1111/J.1464-5491.2004.01332.X
P577
2004-12-01T00:00:00Z